CRSP CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 30% planned / 70% discretionary
Largest single sale: $2.4M.
Where they traded
Last open-market purchase: April 3, 2025 — 1.6 years ago, by Patel Naimish .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | Chief Executive Officer | Sell | 47,837 | $49.78 | $2.4M | 311,899 −13.3% of holding | |
| George Simeon | Director | Sell 10b5-1 | 14,514 | $49.63 | $720.4K | 15,486 −48.4% of holding | |
| Kulkarni Samarth | Chief Executive Officer | Sell | 4,098 | $49.26 | $201.9K | 259,736 −1.6% of holding | |
| KASINGER JAMES R. | General Counsel and Secretary | Sell | 1,040 | $49.26 | $51.2K | 95,857 −1.1% of holding | |
| KASINGER JAMES R. | General Counsel and Secretary | Sell 10b5-1 | 1,990 | $60.04 | $119.5K | 94,784 −2.1% of holding | |
| KASINGER JAMES R. | General Counsel and Secretary | Sell 10b5-1 | 10,400 | $60.24 | $626.5K | 94,784 −9.9% of holding | |
| Behbahani Ali | Director | Sell | 13,679 | $57.09 | $780.9K | 16,637 −45.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.